31 May 2017


(“Sareum” or “the Company”)

Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. yesterday stating that selection patents* that explicitly protect the Chk1 inhibitor SRA737 have been granted in the USA and Europe, extending its protection period to the year 2033 in the US.

The full announcement can be found on Sierra Oncology’s IR website**.

Dr Tim Mitchell, CEO of Sareum, commented: “SRA737 is a valuable asset to Sareum through its licence to Sierra Oncology. We are pleased to see that patents to protect it have been granted in these major territories.”

Sierra Oncology holds exclusive and worldwide rights for the Chk1 inhibitor, SRA737, having licensed the programme from Sareum’s co-investment partner, the CRT Pioneer Fund in September 2016. This announcement does not trigger any milestone payments under the terms of the agreement.

* Patent nos US 9,663,503, EU 2855448


For further information, please contact:

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce

020 3764 2341

The Communications Portfolio (Sareum Media enquiries)


Ariane Comstive

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -